Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
completion around

Description

Summary

Official Title

A Phase 1/2 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Patients With MET Overexpressing Advanced Cancer

Keywords

Advanced NSCLC, Non-small cell lung cancer, Mesenchymal epithelial transition factor (MET), MET Overexpressing Advanced Cancer, Cemiplimab, REGN5093-M114

Eligibility

Locations

  • University of California Irvine School of Medicine - Suite 400, Room 407
    Orange California 92868 United States
  • University of Colorado Hospital Anshutz Outpatient Pavillion
    Denver Colorado 80045 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Regeneron Pharmaceuticals
ID
NCT04982224
Phase
Phase 1/2 Non-Small Cell Lung Cancer Research Study
Study Type
Interventional
Participants
About 30 people participating
Last Updated